Soligenix Inc.

12/16/2024 | Press release | Distributed by Public on 12/16/2024 06:31

Soligenix Initiates Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma